Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AZZ CEO David Dingus Diagnosed With Pancreatic Cancer

RELATED NEWS
Trade AZZ now with 

AZZ Inc. (AZZ: Quote) said Monday that its President and Chief Executive Officer, David Dingus, has been recently diagnosed with cancer of the pancreas.

Dingus will begin an aggressive treatment commencing the week of March 4.

It is anticipated that during this period of treatment, all day-to-day operations will continue to be conducted by the organization currently in place, the company said and added that Dingus will continue in his role of Chief Executive Officer.

AZZ said Dingus and the senior management team will continue to work with the Board of Directors to continue to seek out all opportunities for profit enhancement, growth and expansion of the existing businesses and the successful implementation of the Aquilex SRO acquisition should the company receive the anticipated government approval to proceed.

Dingus may have a reduced work schedule during certain periods of his treatment, but he is not expected to be away for any extended periods of time, the company noted.

Click here to receive FREE breaking news email alerts for AZZ incorporated and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.